Publication Date
4-1-2023
Journal
Heart Failure - JACC
DOI
10.1016/j.jchf.2022.12.005
PMID
36881398
PMCID
PMC10248756
PubMedCentral® Posted Date
6-8-2023
PubMedCentral® Full Text Version
Author MSS
Published Open-Access
yes
Keywords
Humans, Aged, Heart Failure, Biomarkers, Prognosis, Atherosclerosis, Echocardiography, Natriuretic Peptide, Brain, Peptide Fragments, heart failure stages, pre-heart failure, cardiovascular risk, heart failure prevention, Stage B heart failure
Abstract
BACKGROUND: The recent heart failure (HF) guideline recommends the inclusion of cardiac biomarkers in defining Stage B HF.
OBJECTIVES: The authors evaluated the impact of incorporating cardiac biomarkers to reclassify HF in 5,324 participants (mean age: 75.8 years) without prevalent HF enrolled in the ARIC (Atherosclerosis Risk In Communities) study and assessed prognosis of Stage B using cardiac biomarkers.
METHODS: Using N-terminal pro-B-type natriuretic peptide (/mL or ≥125 pg/mL), high-sensitivity troponin T (/L or ≥14 ng/L), and abnormal cardiac structure/function by echocardiography, individuals were classified as Stage A
RESULTS: Overall, 4,326 (81.3%) individuals were classified as Stage B
CONCLUSIONS: Incorporating biomarkers based on the new HF guideline reclassified approximately 1 in 5 older adults without prevalent HF to Stage B. The routine measurement of biomarkers can help to identify individuals at higher HF risk who may benefit most from HF prevention efforts.